Magnolia Capital Advisors LLC Makes New Investment in AbbVie Inc. $ABBV

Key Points

• Magnolia Capital Advisors initiated a position in AbbVie during the second quarter, purchasing 16,722 shares valued at approximately $4.2 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie’s stock.
• AbbVie reported strong pipeline and product developments, including positive Phase 3 results for etentamig and the completion of its approximately $10.9 billion Apogee Therapeutics acquisition. Skyrizi and Rinvoq sales rose 24% and 25%, respectively, helping offset continued Humira revenue declines.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $275.95, while AbbVie recently exceeded quarterly earnings and revenue expectations. The company also reaffirmed its 2026 adjusted EPS outlook and declared a quarterly dividend of $1.73.

Magnolia Capital Advisors LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,722 shares of the company's stock, valued at approximately $4,208,000.

A number of other large investors have also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the 4th quarter worth about $28,000. Imprint Wealth LLC boosted its holdings in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares during the period. Burk Holdings LLC bought a new position in AbbVie during the 2nd quarter worth $30,000. Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in AbbVie during the fourth quarter worth $31,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 15th. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. Cantor Fitzgerald boosted their price objective on AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Finally, Wells Fargo & Company boosted their target price on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $275.95.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

AbbVie Stock Performance

NYSE:ABBV opened at $256.27 on Friday. The business has a 50 day moving average price of $254.66 and a 200-day moving average price of $230.06. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market cap of $452.78 billion, a PE ratio of 72.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source